Vanguard Group Inc 89bio, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in 89bio, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,804,953 shares of ETNB stock, worth $34.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,804,953
Previous 4,722,971
1.74%
Holding current value
$34.5 Million
Previous $55 Million
29.99%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ETNB
# of Institutions
157Shares Held
107MCall Options Held
65KPut Options Held
1.2M-
Ra Capital Management, L.P. Boston, MA14.2MShares$102 Million1.71% of portfolio
-
Janus Henderson Group PLC London, X013.3MShares$95.5 Million0.06% of portfolio
-
Suvretta Capital Management, LLC New York, NY8.03MShares$57.7 Million2.69% of portfolio
-
Bvf Inc San Francisco, CA7.57MShares$54.4 Million1.85% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$53.1 Million0.99% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $334M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...